ANDA 216436, held by Biocon Pharma. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 216436 (Atorvastatin Calcium), held by Biocon Pharma, was first approved by FDA on Nov 23, 2022, with 2 approved supplements and 0 published complete response letters.
Atorvastatin calcium tablets are indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 23, 2022 | Original application | Approved | None posted |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Jan 10, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 20, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 23, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters